Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer: ASCO Guideline Update

This US guidance, produced following an expert panel review of an RCT recommends 14 cycles of adjuvant trastuzumab emtansine in HER2+ve breast cancer with pathologic invasive residual disease after surgery after standard preoperative chemotherapy and HER2-targeted therapy.

Journal of Clinical Oncology